[{"id":"381bf29b-94cb-4456-94ac-4f2cac19d9f0","acronym":"","url":"https://clinicaltrials.gov/study/NCT06852014","created_at":"2025-03-03T09:58:31.668Z","updated_at":"2025-03-03T09:58:31.668Z","phase":"","brief_title":"Effects of Peptamen 1.6 in Malnourished Patients (or At Risk) with Pancreatic Neoplasia Undergoing Cephalic Pancreaticoduodenectomy (CPD): a Mechanistic Study","source_id_and_acronym":"NCT06852014","lead_sponsor":"Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud","biomarkers":" IL6 • TNFA","pipe":"","alterations":" ","tags":["IL6 • TNFA"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 04/01/2025","start_date":" 04/01/2025","primary_txt":" Primary completion: 06/01/2026","primary_completion_date":" 06/01/2026","study_txt":" Completion: 09/01/2026","study_completion_date":" 09/01/2026","last_update_posted":"2025-02-28"},{"id":"247549cd-8895-4562-99d4-e47d7bf8dd69","acronym":"","url":"https://clinicaltrials.gov/study/NCT00923104","created_at":"2021-01-18T03:34:22.610Z","updated_at":"2025-02-25T13:48:00.941Z","phase":"","brief_title":"An Exploratory Evaluation of Biomarkers in Blister Fluid in Healthy Volunteers and Irradiated Skin","source_id_and_acronym":"NCT00923104","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" IL6 • TNFA • IL1B • MMP1","pipe":"","alterations":" ","tags":["IL6 • TNFA • IL1B • MMP1"],"overall_status":"Completed","enrollment":" Enrollment 61","initiation":"Initiation: 04/23/2009","start_date":" 04/23/2009","primary_txt":"","primary_completion_date":"","study_txt":"","study_completion_date":"","last_update_posted":"2025-02-21"},{"id":"48df85e5-b786-45f4-a391-eab53ca69d44","acronym":"AMPLIFY","url":"https://clinicaltrials.gov/study/NCT04000880","created_at":"2024-02-21T19:24:47.029Z","updated_at":"2025-02-25T13:48:43.597Z","phase":"","brief_title":"Adapting Multiple Behavior Interventions That Effectively Improve Cancer Survivor Health Cancer Survivor Health","source_id_and_acronym":"NCT04000880 - AMPLIFY","lead_sponsor":"University of Alabama at Birmingham","biomarkers":" IL6 • TNFA • CRP","pipe":"","alterations":" ","tags":["IL6 • TNFA • CRP"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 603","initiation":"Initiation: 03/04/2020","start_date":" 03/04/2020","primary_txt":" Primary completion: 04/01/2025","primary_completion_date":" 04/01/2025","study_txt":" Completion: 04/01/2025","study_completion_date":" 04/01/2025","last_update_posted":"2025-02-21"},{"id":"c9fa59c0-ee9b-4c5f-baf7-8f04f47fe653","acronym":"","url":"https://clinicaltrials.gov/study/NCT05630794","created_at":"2022-11-30T18:57:52.049Z","updated_at":"2025-02-25T13:41:21.187Z","phase":"Phase 1","brief_title":"Testing ONC201 to Prevent Colorectal Cancer","source_id_and_acronym":"NCT05630794","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BCL2 • IL6 • TNFA • IL10 • CASP3 • GZMA • IL17A • PRL","pipe":"","alterations":" ","tags":["BCL2 • IL6 • TNFA • IL10 • CASP3 • GZMA • IL17A • PRL"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Modeyso (dordaviprone)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 24","initiation":"Initiation: 03/30/2025","start_date":" 03/30/2025","primary_txt":" Primary completion: 01/01/2026","primary_completion_date":" 01/01/2026","study_txt":" Completion: 01/01/2028","study_completion_date":" 01/01/2028","last_update_posted":"2025-02-21"},{"id":"86782c45-c567-43a8-9173-9539c1107862","acronym":"","url":"https://clinicaltrials.gov/study/NCT06825221","created_at":"2025-02-25T15:16:27.848Z","updated_at":"2025-02-25T15:16:27.848Z","phase":"","brief_title":"Effect of Immune Formula in Gastrointestinal Cancer Patients Undergoing Cancer Surgery","source_id_and_acronym":"NCT06825221","lead_sponsor":"Chulalongkorn University","biomarkers":" IL6 • TNFA • CRP","pipe":"","alterations":" ","tags":["IL6 • TNFA • CRP"],"overall_status":"Completed","enrollment":" Enrollment 30","initiation":"Initiation: 04/01/2023","start_date":" 04/01/2023","primary_txt":" Primary completion: 07/31/2024","primary_completion_date":" 07/31/2024","study_txt":" Completion: 09/30/2024","study_completion_date":" 09/30/2024","last_update_posted":"2025-02-13"},{"id":"f48f1b5b-016c-486a-b2f8-c14558815182","acronym":"","url":"https://clinicaltrials.gov/study/NCT03794349","created_at":"2023-11-21T16:15:50.470Z","updated_at":"2025-02-25T15:11:00.647Z","phase":"Phase 2","brief_title":"Irinotecan Hydrochloride, Temozolomide, and Dinutuximab With or Without Eflornithine in Treating Patients With Relapsed or Refractory Neuroblastoma","source_id_and_acronym":"NCT03794349","lead_sponsor":"Children's Oncology Group","biomarkers":" IFNG • IL6 • CD276 • TNFA","pipe":"","alterations":" ","tags":["IFNG • IL6 • CD276 • TNFA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temozolomide • irinotecan • Qarziba (dinutuximab beta) • Unituxin (dinutuximab) • Leukine (sargramostim)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 95","initiation":"Initiation: 07/08/2019","start_date":" 07/08/2019","primary_txt":" Primary completion: 03/31/2025","primary_completion_date":" 03/31/2025","study_txt":" Completion: 03/31/2025","study_completion_date":" 03/31/2025","last_update_posted":"2025-02-13"},{"id":"c3f91db3-f89a-454a-9211-dc69a8dcc486","acronym":"EOSDOEOSQ","url":"https://clinicaltrials.gov/study/NCT06773143","created_at":"2025-02-25T15:37:59.408Z","updated_at":"2025-02-25T15:37:59.408Z","phase":"","brief_title":"Effect of Subanesthetic Dose of Esketamine on Sleep Quality","source_id_and_acronym":"NCT06773143 - EOSDOEOSQ","lead_sponsor":"Nanjing First Hospital, Nanjing Medical University","biomarkers":" IL6 • TNFA • BDNF","pipe":"","alterations":" ","tags":["IL6 • TNFA • BDNF"],"overall_status":"Recruiting","enrollment":" Enrollment 184","initiation":"Initiation: 12/30/2024","start_date":" 12/30/2024","primary_txt":" Primary completion: 12/31/2026","primary_completion_date":" 12/31/2026","study_txt":" Completion: 04/30/2027","study_completion_date":" 04/30/2027","last_update_posted":"2025-02-10"},{"id":"9eaff877-3912-4232-9211-c73f401a599e","acronym":"","url":"https://clinicaltrials.gov/study/NCT06741540","created_at":"2025-02-25T16:41:58.840Z","updated_at":"2025-02-25T16:41:58.840Z","phase":"","brief_title":"Effects of TDCS Intervention on Neoadjuvant Chemotherapy in Breast Cancer Patients with Mild to Moderate Depression","source_id_and_acronym":"NCT06741540","lead_sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","biomarkers":" HER-2 • ER • PGR • IL6 • TNFA","pipe":" | ","alterations":" HER-2 expression","tags":["HER-2 • ER • PGR • IL6 • TNFA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 expression"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 01/01/2025","start_date":" 01/01/2025","primary_txt":" Primary completion: 01/01/2027","primary_completion_date":" 01/01/2027","study_txt":" Completion: 01/01/2027","study_completion_date":" 01/01/2027","last_update_posted":"2025-02-07"},{"id":"ad314edd-2963-47ac-86cd-5f06a81ee36e","acronym":"","url":"https://clinicaltrials.gov/study/NCT06005649","created_at":"2023-08-22T15:08:54.438Z","updated_at":"2025-02-25T16:33:37.494Z","phase":"Phase 1/2","brief_title":"Clinical Trial of HY004 Cell Injection in the Treatment of Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma","source_id_and_acronym":"NCT06005649","lead_sponsor":"Juventas Cell Therapy Ltd.","biomarkers":" BCL2 • BCL6 • IL6 • CD22","pipe":" | ","alterations":" CD19 positive","tags":["BCL2 • BCL6 • IL6 • CD22"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • HY004"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 80","initiation":"Initiation: 06/01/2025","start_date":" 06/01/2025","primary_txt":" Primary completion: 06/01/2026","primary_completion_date":" 06/01/2026","study_txt":" Completion: 06/01/2027","study_completion_date":" 06/01/2027","last_update_posted":"2025-02-07"},{"id":"d7d0a6de-b0e3-4648-b4e9-ec298fd54104","acronym":"B-ALL","url":"https://clinicaltrials.gov/study/NCT06009107","created_at":"2024-03-13T08:35:11.520Z","updated_at":"2025-02-25T16:33:38.314Z","phase":"Phase 1/2","brief_title":"A Study of HY004 Treatment in Adult Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (r/r B-ALL)","source_id_and_acronym":"NCT06009107 - B-ALL","lead_sponsor":"Juventas Cell Therapy Ltd.","biomarkers":" IL6","pipe":" | ","alterations":" CD19 expression","tags":["IL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • HY004"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 06/30/2025","start_date":" 06/30/2025","primary_txt":" Primary completion: 12/30/2026","primary_completion_date":" 12/30/2026","study_txt":" Completion: 12/30/2027","study_completion_date":" 12/30/2027","last_update_posted":"2025-02-07"},{"id":"93e5786d-1ac5-44c3-afc1-90d14b57f062","acronym":"REBOUND","url":"https://clinicaltrials.gov/study/NCT04188678","created_at":"2021-01-18T20:25:04.337Z","updated_at":"2025-02-25T16:37:38.653Z","phase":"","brief_title":"Resiliency in Older Adults Undergoing Bone Marrow Transplant","source_id_and_acronym":"NCT04188678 - REBOUND","lead_sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","biomarkers":" IL6","pipe":"","alterations":" ","tags":["IL6"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 130","initiation":"Initiation: 09/28/2018","start_date":" 09/28/2018","primary_txt":" Primary completion: 03/26/2025","primary_completion_date":" 03/26/2025","study_txt":" Completion: 05/30/2025","study_completion_date":" 05/30/2025","last_update_posted":"2025-02-06"},{"id":"76e5fabc-947c-4440-ba90-48fba05bcaa1","acronym":"","url":"https://clinicaltrials.gov/study/NCT01850888","created_at":"2021-01-18T08:15:43.798Z","updated_at":"2025-02-25T16:51:18.108Z","phase":"","brief_title":"MIBG for Refractory Neuroblastoma and Pheochromocytoma","source_id_and_acronym":"NCT01850888","lead_sponsor":"Masonic Cancer Center, University of Minnesota","biomarkers":" IL6 • IL2","pipe":"","alterations":" ","tags":["IL6 • IL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Neulasta (pegfilgrastim) • Azedra (iobenguane I 131)"],"overall_status":"Suspended","enrollment":" Enrollment 100","initiation":"Initiation: 12/01/2013","start_date":" 12/01/2013","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2025-02-04"},{"id":"c18480ea-e56b-4074-80ac-afaf290dce63","acronym":"","url":"https://clinicaltrials.gov/study/NCT04556045","created_at":"2021-01-18T21:46:44.852Z","updated_at":"2025-02-25T16:53:16.785Z","phase":"","brief_title":"Exercise Therapy and Radiation Therapy (EXERT) for Metastatic Prostate Cancer","source_id_and_acronym":"NCT04556045","lead_sponsor":"Case Comprehensive Cancer Center","biomarkers":" IL6 • TNFA • CXCL8 • IL10 • IL15 • IL1B","pipe":"","alterations":" ","tags":["IL6 • TNFA • CXCL8 • IL10 • IL15 • IL1B"],"overall_status":"Recruiting","enrollment":" Enrollment 80","initiation":"Initiation: 12/11/2023","start_date":" 12/11/2023","primary_txt":" Primary completion: 06/01/2025","primary_completion_date":" 06/01/2025","study_txt":" Completion: 06/01/2026","study_completion_date":" 06/01/2026","last_update_posted":"2025-02-04"},{"id":"aa4b31fa-23aa-4579-8b21-8edc7bf3eded","acronym":"Phyto-2022-01","url":"https://clinicaltrials.gov/study/NCT05664477","created_at":"2023-12-07T22:15:15.725Z","updated_at":"2025-02-25T17:25:56.357Z","phase":"Phase 2","brief_title":"PhytoSERM to Prevent Menopause Associated Decline in Brain Metabolism and Cognition","source_id_and_acronym":"NCT05664477 - Phyto-2022-01","lead_sponsor":"Roberta Brinton","biomarkers":" IL6","pipe":"","alterations":" ","tags":["IL6"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 01/10/2024","start_date":" 01/10/2024","primary_txt":" Primary completion: 01/31/2027","primary_completion_date":" 01/31/2027","study_txt":" Completion: 01/31/2027","study_completion_date":" 01/31/2027","last_update_posted":"2025-01-31"},{"id":"7cf69f5a-aff7-4427-8529-8794fca88989","acronym":"","url":"https://clinicaltrials.gov/study/NCT05268991","created_at":"2022-03-07T18:54:01.348Z","updated_at":"2025-02-25T17:37:39.901Z","phase":"","brief_title":"Aging and Frailty Study","source_id_and_acronym":"NCT05268991","lead_sponsor":"Wake Forest University Health Sciences","biomarkers":" IL6 • TNFA","pipe":"","alterations":" ","tags":["IL6 • TNFA"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 25","initiation":"Initiation: 05/02/2022","start_date":" 05/02/2022","primary_txt":" Primary completion: 01/07/2025","primary_completion_date":" 01/07/2025","study_txt":" Completion: 07/01/2025","study_completion_date":" 07/01/2025","last_update_posted":"2025-01-29"},{"id":"d7cdffc4-f22c-4043-a30f-9144f9def49d","acronym":"","url":"https://clinicaltrials.gov/study/NCT04720209","created_at":"2021-01-22T12:54:16.002Z","updated_at":"2025-02-25T17:36:58.808Z","phase":"","brief_title":"Taking AIM at Breast Cancer","source_id_and_acronym":"NCT04720209","lead_sponsor":"Dana-Farber Cancer Institute","biomarkers":" PGR • IL6 • TNFA","pipe":"","alterations":" ","tags":["PGR • IL6 • TNFA"],"overall_status":"Recruiting","enrollment":" Enrollment 300","initiation":"Initiation: 08/13/2021","start_date":" 08/13/2021","primary_txt":" Primary completion: 06/15/2025","primary_completion_date":" 06/15/2025","study_txt":" Completion: 06/15/2026","study_completion_date":" 06/15/2026","last_update_posted":"2025-01-29"},{"id":"2e87885c-4e7c-4eee-af7f-c60a1af4ea15","acronym":"SPIRAL","url":"https://clinicaltrials.gov/study/NCT06785974","created_at":"2025-02-25T19:12:33.814Z","updated_at":"2025-02-25T19:12:33.814Z","phase":"Phase 4","brief_title":"Statins to Prevent Immune Checkpoint Inhibitor-induced PRogression of AtherosLerosis","source_id_and_acronym":"NCT06785974 - SPIRAL","lead_sponsor":"Erasmus Medical Center","biomarkers":" IL6 • TNFA • IL10 • IL1B • CRP","pipe":"","alterations":" ","tags":["IL6 • TNFA • IL10 • IL1B • CRP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e atorvastatin"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 140","initiation":"Initiation: 02/01/2025","start_date":" 02/01/2025","primary_txt":" Primary completion: 02/01/2027","primary_completion_date":" 02/01/2027","study_txt":" Completion: 02/01/2030","study_completion_date":" 02/01/2030","last_update_posted":"2025-01-22"},{"id":"c7ada12b-b24c-42ce-852e-8af29310368c","acronym":"","url":"https://clinicaltrials.gov/study/NCT06784258","created_at":"2025-02-25T19:12:28.485Z","updated_at":"2025-02-25T19:12:28.485Z","phase":"Phase 4","brief_title":"Comparison of Inflammatory Factors, Pain Scale, and Postoperative Recovery Quality (QOR - 15) in Patients Undergoing Colorectal Cancer Surgery with Conventional General Anesthesia Techniques Compared to General Anesthesia Combined with Epidural Anesthesia At Prof. Ngoerah Hospital","source_id_and_acronym":"NCT06784258","lead_sponsor":"Udayana University","biomarkers":" IL6","pipe":"","alterations":" ","tags":["IL6"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 44","initiation":"Initiation: 12/28/2024","start_date":" 12/28/2024","primary_txt":" Primary completion: 01/28/2025","primary_completion_date":" 01/28/2025","study_txt":" Completion: 01/28/2025","study_completion_date":" 01/28/2025","last_update_posted":"2025-01-20"},{"id":"4346ba5f-67b8-4706-8e12-549591ad58c7","acronym":"","url":"https://clinicaltrials.gov/study/NCT06696768","created_at":"2025-02-25T20:15:51.863Z","updated_at":"2025-02-25T20:15:51.863Z","phase":"Phase 1","brief_title":"Clinical Trial of an Anti-cancer Drug, CA-4948 (Emavusertib), in Combination With Chemotherapy Treatment (FOLFOX Plus Bevacizumab) in Metastatic Colorectal Cancer","source_id_and_acronym":"NCT06696768","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" IFNG • IL6 • CCL2 • CXCL1 • IRAK4","pipe":"","alterations":" ","tags":["IFNG • IL6 • CCL2 • CXCL1 • IRAK4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • oxaliplatin • Aybintio (bevacizumab biosimilar) • leucovorin calcium • Vegzelma (bevacizumab-adcd) • Avzivi (bevacizumab-tnjn) • emavusertib (CA-4948) • fluorouracil topical"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 24","initiation":"Initiation: 02/28/2025","start_date":" 02/28/2025","primary_txt":" Primary completion: 10/31/2025","primary_completion_date":" 10/31/2025","study_txt":" Completion: 10/31/2025","study_completion_date":" 10/31/2025","last_update_posted":"2025-01-16"},{"id":"08da958b-deab-46fd-9448-9e7d0dc1d817","acronym":"KEYNOTE B84","url":"https://clinicaltrials.gov/study/NCT04815720","created_at":"2021-03-25T11:52:15.829Z","updated_at":"2025-02-25T16:11:18.429Z","phase":"Phase 1/2","brief_title":"Pepinemab in Combination With Pembrolizumab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck","source_id_and_acronym":"NCT04815720 - KEYNOTE B84","lead_sponsor":"Vaccinex Inc.","biomarkers":" PD-L1 • IFNG • IL6 • TNFA • CD4 • IL2 • IL10 • TGFB1","pipe":"","alterations":" ","tags":["PD-L1 • IFNG • IL6 • TNFA • CD4 • IL2 • IL10 • TGFB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • pepinemab (VX15)"],"overall_status":"Completed","enrollment":" Enrollment 49","initiation":"Initiation: 08/09/2021","start_date":" 08/09/2021","primary_txt":" Primary completion: 07/24/2024","primary_completion_date":" 07/24/2024","study_txt":" Completion: 07/24/2024","study_completion_date":" 07/24/2024","last_update_posted":"2025-01-08"},{"id":"29969cfe-2b37-4195-9895-8e10c1f2fc4d","acronym":"","url":"https://clinicaltrials.gov/study/NCT06482905","created_at":"2025-02-26T07:12:20.689Z","updated_at":"2025-02-26T07:12:20.689Z","phase":"Phase 1","brief_title":"Safety and Efficacy Study of TX103 CAR-T Cell Therapy for Recurrent or Progressive Grade 4 Glioma.","source_id_and_acronym":"NCT06482905","lead_sponsor":"Tcelltech Inc.","biomarkers":" IFNG • IL6 • TNFA • IL2 • IL10","pipe":"","alterations":" ","tags":["IFNG • IL6 • TNFA • IL2 • IL10"],"overall_status":"Recruiting","enrollment":" Enrollment 52","initiation":"Initiation: 09/04/2024","start_date":" 09/04/2024","primary_txt":" Primary completion: 09/01/2026","primary_completion_date":" 09/01/2026","study_txt":" Completion: 06/01/2027","study_completion_date":" 06/01/2027","last_update_posted":"2025-01-08"},{"id":"b3d0abdf-0279-4d36-aa6d-69fe2e62ba80","acronym":"SHR-1316-SCLC-LN-001","url":"https://clinicaltrials.gov/study/NCT06480864","created_at":"2025-02-26T07:35:04.037Z","updated_at":"2025-02-26T07:35:04.037Z","phase":"","brief_title":"Adebrelimab Plus Apatinib for Maintenance Therapy of Extensive Stage Small Cell Lung Cancer","source_id_and_acronym":"NCT06480864 - SHR-1316-SCLC-LN-001","lead_sponsor":"Yunpeng Liu","biomarkers":" PD-L1 • IL6 • IL10","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1 • IL6 • IL10"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • carboplatin • AiTan (rivoceranib) • etoposide IV • AiRuiLi (adebrelimab)"],"overall_status":"Recruiting","enrollment":" Enrollment 38","initiation":"Initiation: 08/09/2024","start_date":" 08/09/2024","primary_txt":" Primary completion: 08/01/2025","primary_completion_date":" 08/01/2025","study_txt":" Completion: 08/01/2026","study_completion_date":" 08/01/2026","last_update_posted":"2025-01-06"},{"id":"e083e3f6-9297-475c-8844-e43c062a3d0a","acronym":"DAANCE","url":"https://clinicaltrials.gov/study/NCT06749210","created_at":"2025-02-26T07:40:40.489Z","updated_at":"2025-02-26T07:40:40.489Z","phase":"Phase 2","brief_title":"DAANCE FOR CHEMOTHERAPY-INDUCED NEUROPATHY","source_id_and_acronym":"NCT06749210 - DAANCE","lead_sponsor":"Ohio State University Comprehensive Cancer Center","biomarkers":" IL6 • TNFA • IL10 • BDNF • GFAP","pipe":"","alterations":" ","tags":["IL6 • TNFA • IL10 • BDNF • GFAP"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 140","initiation":"Initiation: 01/01/2025","start_date":" 01/01/2025","primary_txt":" Primary completion: 09/01/2030","primary_completion_date":" 09/01/2030","study_txt":" Completion: 09/01/2030","study_completion_date":" 09/01/2030","last_update_posted":"2025-01-06"},{"id":"84edb0cb-23b4-41c9-a4af-3815707a7019","acronym":"","url":"https://clinicaltrials.gov/study/NCT05958719","created_at":"2025-02-26T07:45:46.896Z","updated_at":"2025-02-26T07:45:46.896Z","phase":"Phase 2","brief_title":"Chidamide in Combination With Azacitidine, Liposomal Mitoxantrone, and Prednisone (CAMP Regimen) for the Treatment of Previously Untreated Nodal TFH Cell Lymphoma","source_id_and_acronym":"NCT05958719","lead_sponsor":"Institute of Hematology \u0026 Blood Diseases Hospital, China","biomarkers":" IFNG • IL6 • TNFA • IL10 • IFNA1","pipe":"","alterations":" ","tags":["IFNG • IL6 • TNFA • IL10 • IFNA1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e azacitidine • prednisone • Epidaza (chidamide) • Duoenda (mitoxantrone liposomal)"],"overall_status":"Recruiting","enrollment":" Enrollment 37","initiation":"Initiation: 03/02/2023","start_date":" 03/02/2023","primary_txt":" Primary completion: 12/30/2026","primary_completion_date":" 12/30/2026","study_txt":" Completion: 03/02/2027","study_completion_date":" 03/02/2027","last_update_posted":"2024-12-30"}]